HARBIN, China, Jan. 12, 2011 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that it has engaged RedChip Companies, Inc., to lead its public and investor relations efforts.
Yin Wang, Chairman and CEO of Weikang, stated, "We selected RedChip based on their proven track record of increasing investor awareness for emerging growth companies, as well as their international presence and innovative multimedia platform of products and services. We are confident that RedChip will help us attract new investors while strengthening our relationships with current shareholders."
"We are pleased to have the opportunity to represent Weikang," said Dave Gentry, President of RedChip Companies, Inc. "China is expected to become the world's third-largest pharmaceutical market by 2020, with market growth driven by national healthcare reform initiatives and a rapidly aging population. Weikang has an impressive portfolio of high-margin pharmaceutical and nutritional products and has achieved strong revenue and net income growth in recent years. We look forward to implementing a comprehensive investor and media relations program and introducing them to our investor network."
About Weikang Bio-Technology Group Co., Inc.
Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP-certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang Pharmaceutical Co., Ltd. For more information, please visit http://www.weikangbio.com.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
SOURCE Weikang Bio-Technology Group Co., Inc.